Research Article
Denosumab for Elderly Men with Osteoporosis: A Cost-Effectiveness Analysis from the US Payer Perspective
Table 5
Cost-effectiveness results: base-case.
| | | Totals |
Incremental | ICERs | | | Cost | LYs | QALYs | Cost | LYs | QALYs | Cost per LY saved | Cost per QALY gained |
| | Generic alendronate | $31,456 | 7.9007 | 5.9866 | — | — | — | Ref. | Ref. | | Denosumab | $32,334 | 7.9339 | 6.0386 | $878 | 0.0333 | 0.0520 | $26,389 | $16,888 | | Zoledronate | $35,138 | 7.9132 | 6.0037 | $2,804 | −0.0208 | −0.0350 | Dominated | Dominated | | Risedronate | $35,232 | 7.8941 | 5.9760 | $2,899 | −0.0399 | −0.0626 | Dominated | Dominated | | Ibandronate | $35,550 | 7.8867 | 5.9663 | $3,216 | −0.0472 | −0.0723 | Dominated | Dominated | | Teriparatide | $48,828 | 7.9308 | 6.0279 | $16,495 | −0.0031 | −0.0107 | Dominated | Dominated |
|
|
Numbers may not add up due to rounding.
|
